Program
TB006
Its studies are mostly in Alzheimer Disease · Parkinson Disease · Ischemic Stroke · COVID-19, led by TrueBinding.
Furthest: phase 2, since Sep 24, 20216 company-led studies, 1 open or runningNext primary completion: Nov 28, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TrueBinding | 61 open or running | phase 2since Sep 24, 2021 | Mar 11, 2021 | Nov 28, 2026phase 2 · NCT06773962 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2021First study: phase 1 study in COVID-19First studyNCT04801056
- May 18, 2021Phase 1 study in Alzheimer DiseaseNCT04920786 · 48 enrolled · United States
- Sep 24, 2021Phase 2 study in Alzheimer DiseaseNCT05074498 · 154 enrolled · United States
- Dec 1, 2021Phase 2 study in Ischemic StrokeNCT05156827
- Jul 25, 2022Phase 2 study in Alzheimer DiseaseNCT05476783 · 119 enrolled · United States
- Jan 8, 2025Phase 2 study in Parkinson DiseaseNCT06773962 · 62 enrolled · United States
Ahead
- Nov 28, 2026Primary completion: phase 2 study in Parkinson DiseaseNCT06773962
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06773962Parkinson Disease · United States | 2 | Active, not recruiting | Nov 28, 2026 | 62 |
| NCT05476783Alzheimer Disease · United States | 2 | Terminated | Nov 17, 2023 | 119 |
| NCT05156827Ischemic Stroke | 2 | Withdrawn | Dec 18, 2023 | 0 |
| NCT05074498Alzheimer Disease · United States | 2 | Completed | Oct 13, 2022 | 154 |
| NCT04920786Alzheimer Disease · United States | 1 | Completed | May 3, 2022 | 48 |
| NCT04801056COVID-19 | 1 | Withdrawn | Sep 1, 2021 | 0 |
How it is read
Names in the registry
- “TB006”, 6 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 3 studies
- Parkinson Disease, 1 study
- Ischemic Stroke, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.